666 related articles for article (PubMed ID: 37468460)
1. Vaccine adjuvants: mechanisms and platforms.
Zhao T; Cai Y; Jiang Y; He X; Wei Y; Yu Y; Tian X
Signal Transduct Target Ther; 2023 Jul; 8(1):283. PubMed ID: 37468460
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor agonists as cancer vaccine adjuvants.
Jeon D; Hill E; McNeel DG
Hum Vaccin Immunother; 2024 Dec; 20(1):2297453. PubMed ID: 38155525
[TBL] [Abstract][Full Text] [Related]
3. Vaccine adjuvants: Tailoring innate recognition to send the right message.
Lavelle EC; McEntee CP
Immunity; 2024 Apr; 57(4):772-789. PubMed ID: 38599170
[TBL] [Abstract][Full Text] [Related]
4. Synthetic vaccines: the role of adjuvants in immune targeting.
Jiang ZH; Koganty RR
Curr Med Chem; 2003 Aug; 10(15):1423-39. PubMed ID: 12871139
[TBL] [Abstract][Full Text] [Related]
5. Exploration of Pattern Recognition Receptor Agonists as Candidate Adjuvants.
Ong GH; Lian BSX; Kawasaki T; Kawai T
Front Cell Infect Microbiol; 2021; 11():745016. PubMed ID: 34692565
[TBL] [Abstract][Full Text] [Related]
6. Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.
Kaur A; Kannan D; Mehta SK; Singh S; Salunke DB
Expert Opin Ther Pat; 2018 Nov; 28(11):837-847. PubMed ID: 30280939
[TBL] [Abstract][Full Text] [Related]
7. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
8. Adjuvants and autoimmunity.
Israeli E; Agmon-Levin N; Blank M; Shoenfeld Y
Lupus; 2009 Nov; 18(13):1217-25. PubMed ID: 19880572
[TBL] [Abstract][Full Text] [Related]
9. Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery.
Gause KT; Wheatley AK; Cui J; Yan Y; Kent SJ; Caruso F
ACS Nano; 2017 Jan; 11(1):54-68. PubMed ID: 28075558
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics.
Kaur A; Baldwin J; Brar D; Salunke DB; Petrovsky N
Curr Opin Chem Biol; 2022 Oct; 70():102172. PubMed ID: 35785601
[TBL] [Abstract][Full Text] [Related]
11. Trends in adjuvant development for vaccines: DAMPs and PAMPs as potential new adjuvants.
Miyaji EN; Carvalho E; Oliveira ML; Raw I; Ho PL
Braz J Med Biol Res; 2011 Jun; 44(6):500-13. PubMed ID: 21584443
[TBL] [Abstract][Full Text] [Related]
12. Strategies to link innate and adaptive immunity when designing vaccine adjuvants.
Garlapati S; Facci M; Polewicz M; Strom S; Babiuk LA; Mutwiri G; Hancock RE; Elliott MR; Gerdts V
Vet Immunol Immunopathol; 2009 Mar; 128(1-3):184-91. PubMed ID: 19042032
[TBL] [Abstract][Full Text] [Related]
13. In-depth review of delivery carriers associated with vaccine adjuvants: current status and future perspectives.
Zeng Y; Zou F; Xia N; Li S
Expert Rev Vaccines; 2023; 22(1):681-695. PubMed ID: 37496496
[TBL] [Abstract][Full Text] [Related]
14. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
Li WH; Su JY; Li YM
Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
[TBL] [Abstract][Full Text] [Related]
15. Recent developments in adjuvants for vaccines against infectious diseases.
O'Hagan DT; MacKichan ML; Singh M
Biomol Eng; 2001 Oct; 18(3):69-85. PubMed ID: 11566599
[TBL] [Abstract][Full Text] [Related]
16. Vaccine adjuvants: putting innate immunity to work.
Coffman RL; Sher A; Seder RA
Immunity; 2010 Oct; 33(4):492-503. PubMed ID: 21029960
[TBL] [Abstract][Full Text] [Related]
17. Targeting Pattern Recognition Receptors (PRR) for Vaccine Adjuvantation: From Synthetic PRR Agonists to the Potential of Defective Interfering Particles of Viruses.
Vasou A; Sultanoglu N; Goodbourn S; Randall RE; Kostrikis LG
Viruses; 2017 Jul; 9(7):. PubMed ID: 28703784
[TBL] [Abstract][Full Text] [Related]
18. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity.
Marciani DJ
Drug Discov Today; 2003 Oct; 8(20):934-43. PubMed ID: 14554157
[TBL] [Abstract][Full Text] [Related]
19. Rational design of polymer-based particulate vaccine adjuvants.
Huete-Carrasco J; Lynch RI; Ward RW; Lavelle EC
Eur J Immunol; 2024 Feb; 54(2):e2350512. PubMed ID: 37994660
[TBL] [Abstract][Full Text] [Related]
20. Adjuvants for human vaccines.
Alving CR; Peachman KK; Rao M; Reed SG
Curr Opin Immunol; 2012 Jun; 24(3):310-5. PubMed ID: 22521140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
